Search Results - "Chowers, Y."

Review article: loss of response to anti‐TNF treatments in Crohn’s disease by Ben‐Horin, S., Chowers, Y.

“…Aliment Pharmacol Ther 2011; 33: 987–995 Summary Background  Loss of response to anti‐TNF agents in Crohn’s disease is an emerging clinical problem. Aim  To…”
Get full text

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease by Rahier, J.F., Magro, F., Abreu, C., Armuzzi, A., Ben-Horin, S., Chowers, Y., Cottone, M., de Ridder, L., Doherty, G., Ehehalt, R., Esteve, M., Katsanos, K., Lees, C.W., MacMahon, E., Moreels, T., Reinisch, W., Tilg, H., Tremblay, L., Veereman-Wauters, G., Viget, N., Yazdanpanah, Y., Eliakim, R., Colombel, J.F.

Get full text

Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy by Bar‐Yoseph, H., Levhar, N., Selinger, L., Manor, U., Yavzori, M., Picard, O., Fudim, E., Kopylov, U., Eliakim, R., Ben‐Horin, S., Chowers, Y., Ungar, B.

“…Summary Background Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with…”
Get full text

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease by Mazor, Y., Almog, R., Kopylov, U., Ben Hur, D., Blatt, A., Dahan, A., Waterman, M., Ben‐Horin, S., Chowers, Y.

“…Summary Background Adalimumab is an effective treatment for Crohn's disease (CD). Anti‐adalimumab antibodies (AAA) and low trough serum drug concentrations…”
Get full text

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab by Ungar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., Bar‐Gil Shitrit, A., Eliakim, R., Ben‐Horin, S., Roblin, X.

“…Summary Background Anti‐adalimumab antibodies (AAA) are associated with loss of clinical response (LOR). Addition of an immunomodulator has been shown to…”
Get full text

Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal by Ben‐Horin, S., Chowers, Y., Ungar, B., Kopylov, U., Loebstein, R., Weiss, B., Eliakim, R., Del Tedesco, E., Paul, S., Roblin, X.

“…Summary Background Low drug levels are associated with emerging loss of response to anti‐TNF. However, this may not be the case in patients with long‐term…”
Get full text

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis by Ungar, B., Mazor, Y., Weisshof, R., Yanai, H., Ron, Y., Goren, I., Waizbard, A., Yavzori, M., Fudim, E., Picard, O., Loebstein, R., Kopylov, U., Dotan, I., Chowers, Y., Eliakim, R., Ben‐Horin, S.

“…Summary Background Infliximab is effective as salvage therapy for patients with steroid refractory acute severe ulcerative colitis (UC). Although current data…”
Get full text

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease by Rahier, J F, Ben-Horin, S, Chowers, Y, Conlon, C, De Munter, P, D'Haens, G, Domènech, E, Eliakim, R, Eser, A, Frater, J, Gassull, M, Giladi, M, Kaser, A, Lémann, M, Moreels, T, Moschen, A, Pollok, R, Reinisch, W, Schunter, M, Stange, E F, Tilg, H, Van Assche, G, Viget, N, Vucelic, B, Walsh, A, Weiss, G, Yazdanpanah, Y, Zabana, Y, Travis, S P L, Colombel, J F

Get full text

European evidence-based Consensus on the management of ulcerative colitis: Current management by Travis, S P L, Stange, E F, Lémann, M, Oresland, T, Bemelman, W A, Chowers, Y, Colombel, J F, D'Haens, G, Ghosh, S, Marteau, P, Kruis, W, Mortensen, N J McC, Penninckx, F, Gassull, M

Get full text

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful by Ben-Horin, Shomron, Yavzori, Miri, Katz, Lior, Kopylov, Uri, Picard, Orit, Fudim, Ella, Coscas, Daniel, Bar-Meir, Simon, Goldstein, Itamar, Chowers, Yehuda

“…To localise the immunogenic part of infliximab and evaluate the clinical usefulness of measuring antibodies against infliximab fragments. Observational study…”
Get more information

The development and validation of screening tools for semi-automated surveillance of surgical site infection following various surgeries by Shitrit, Pnina, Chowers, Michal Y, Muhsen, Khitam

“…Surveillance of surgical site infections (SSIs) is essential for better prevention. We developed a screening method for SSIs in adults. The training dataset…”
Get full text

Editorial: anti‐tumour necrosis factor α antibodies – can efficacy be regained? by Bar‐Yoseph, H., Chowers, Y.

“…Linked ContentThis article is linked to Strik et al and Strik, D'Heans papers. To view these articles visit https://doi.org/10.1111/apt.13994 and…”
Get full text

European evidence based consensus on the diagnosis and management of Crohn’s disease: current management by Travis, S P L, Stange, E F, Lémann, M, Öresland, T, Chowers, Y, Forbes, A, D’Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J

“…This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active…”
Get full text

Clinical characteristics of the West Nile fever outbreak, Israel, 2000 by Chowers, Michal Y, Lang, Ruth, Nassar, Faris, Ben-David, Debora, Giladi, Michael, Rubinshtein, Eitan, Itzhaki, Avi, Mishal, Josef, Siegman-Igra, Yardena, Kitzes, Ruth, Pick, Neora, Landau, Zvi, Wolf, Dana, Bin, Hanna, Mendelson, Ella, Pitlik, Silvio D, Weinberger, Miriam

“…West Nile (WN) virus is endemic in Israel. The last reported outbreak had occurred in 1981. From August to October 2000, a large-scale epidemic of WN fever…”
Get full text

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD by Ben-Horin, S., Mazor, Y., Yanai, H., Ron, Y., Kopylov, U., Yavzori, M., Picard, O., Fudim, E., Maor, Y., Lahat, A., Coscas, D., Eliakim, R., Dotan, I., Chowers, Y.

“…Summary Background Anti‐drug antibodies can be elicited by infliximab and adalimumab, but the rate of their decay after therapy is stopped is unknown. Aim To…”
Get full text

A novel device to improve colon cleanliness during colonoscopy by Eliakim, R, Yassin, K, Lachter, J, Chowers, Y

“…Effective colonoscopy depends on adequate visualization of the intestine, which might be ensured by intraprocedural use of a cleansing device. We investigated…”
Get more information

The loss of calretinin expression indicates aganglionosis in Hirschsprung’s disease by Barshack, I, Fridman, E, Goldberg, I, Chowers, Y, Kopolovic, J

“…Background: Hirschsprung’s disease (HD) is a congenital disorder characterised by the absence of ganglion cells in the large bowel, leading to functional…”
Get full text

Taking immunogenicity assessment of therapeutic proteins to the next level by Büttel, I.C., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P., Lubiniecki, A., Krause, R., Mire-Sluis, A., Platts-Mills, T., Ragheb, J.A., Reipert, B.M., Schellekens, H., Seitz, R., Stas, P., Subramanyam, M., Thorpe, R., Trouvin, J.-H., Weise, M., Windisch, J., Schneider, C.K.

“…Therapeutic proteins provide innovative and effective therapies for numerous diseases. However, some of these products are associated with unwanted…”
Get full text

The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease by Ochaion, A, Bar-Yehuda, S, Cohen, S, Barer, F, Patoka, R, Amital, H, Reitblat, T, Reitblat, A, Ophir, J, Konfino, I, Chowers, Y, Ben-Horin, S, Fishman, P

“…The Gi protein associated A(3) adenosine receptor (A(3)AR) was recently defined as a novel anti-inflammatory target. The aim of this study was to look at…”
Get full text

Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review by Chowers, Michal Y., Gottesman, Bat Sheva, Leibovici, Leonard, Pielmeier, Ulrike, Andreassen, Steen, Paul, Mical

“…Objectives Our objectives were to systematically assess the quality of reporting of adverse events (AEs) in publications of randomized trials of highly active…”
Get full text